BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kang L, Pan J, Wu J, Hu J, Sun Q, Tang J. Anti-HBV Drugs: Progress, Unmet Needs, and New Hope. Viruses. 2015;7:4960-4977. [PMID: 26389937 DOI: 10.3390/v7092854] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
Number Citing Articles
1 Hong X, Cai Z, Zhou F, Jin X, Wang G, Ouyang B, Zhang J. Improved pharmacokinetics of tenofovir ester prodrugs strengthened the inhibition of HBV replication and the rebalance of hepatocellular metabolism in preclinical models. Front Pharmacol 2022;13:932934. [DOI: 10.3389/fphar.2022.932934] [Reference Citation Analysis]
2 Wang Y, Wang S, Tao X, Wang Y, Wu Y, Chen N, Hu C, Wang H, Yu S, Sheng R. The SAR-based development of small molecular HBV capsid assembly modulators. Med Chem Res. [DOI: 10.1007/s00044-022-02936-5] [Reference Citation Analysis]
3 Ivanova Bencheva L, Donnici L, Ferrante L, Prandi A, Sinisi R, De Matteo M, Randazzo P, Conti M, Di Lucia P, Bono E, Giustini L, Vittoria Orsale M, Patsilinakos A, Monteagudo E, Iannacone M, Summa V, Guidotti LG, De Francesco R, Di Fabio R. Discovery and Antiviral Profile of New Sulfamoylbenzamide Derivatives as HBV Capsid Assembly Modulators. Bioorg Med Chem Lett 2022;:128904. [PMID: 35868496 DOI: 10.1016/j.bmcl.2022.128904] [Reference Citation Analysis]
4 Wang L, Xia Z, Tang W, Sun Y, Wu Y, Kwok HF, Sun F, Cao Z. p38 activation and viral infection. Expert Rev Mol Med 2022;24. [DOI: 10.1017/erm.2021.29] [Reference Citation Analysis]
5 Tsai HJ, Chuang YW, Yang SS, Chang YZ, Chang HR, Lee TY. Evaluating the renal safety of tenofovir disoproxil fumarate in hepatitis B patients without chronic kidney disease. J Viral Hepat 2021;28:1579-86. [PMID: 34464999 DOI: 10.1111/jvh.13603] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Takayama H, Komura T, Kagaya T, Sugimoto S, Orita N, Asahina Y, Nishikawa M, Ohta H, Kaneko S, Unoura M. Clinical Features and Resistance to Entecavir Monotherapy of Patients with Hepatitis B. Can J Gastroenterol Hepatol 2021;2021:3259833. [PMID: 34422709 DOI: 10.1155/2021/3259833] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Ren Y, Ma Y, Cherukupalli S, Tavis JE, Menéndez-Arias L, Liu X, Zhan P. Discovery and optimization of benzenesulfonamides-based hepatitis B virus capsid modulators via contemporary medicinal chemistry strategies. Eur J Med Chem 2020;206:112714. [PMID: 32949990 DOI: 10.1016/j.ejmech.2020.112714] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
8 Guo X, Chen D, Cai Q, Huang Z, Xu W, Peng L, Chen P. Minicircle DNA vector expressing interferon-lambda-3 inhibits hepatitis B virus replication and expression in hepatocyte-derived cell line. BMC Mol Cell Biol. 2020;21:6. [PMID: 32070272 DOI: 10.1186/s12860-020-00250-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
9 Li Y, Wang G, Liu J, Ouyang L. Quinolizidine alkaloids derivatives from Sophora alopecuroides Linn: Bioactivities, structure-activity relationships and preliminary molecular mechanisms. Eur J Med Chem 2020;188:111972. [PMID: 31884408 DOI: 10.1016/j.ejmech.2019.111972] [Cited by in Crossref: 16] [Cited by in F6Publishing: 29] [Article Influence: 5.3] [Reference Citation Analysis]
10 Birkus G, Snyder C, Jordan R, Kobayashi T, Dick R, Puscau V, Li L, Ramirez R, Willkom M, Morikawa Y, Delaney Iv WE, Schmitz U. Anti-HBV activity of retinoid drugs in vitro versus in vivo. Antiviral Res 2019;169:104538. [PMID: 31226346 DOI: 10.1016/j.antiviral.2019.104538] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
11 Nijampatnam B, Liotta DC. Recent advances in the development of HBV capsid assembly modulators. Current Opinion in Chemical Biology 2019;50:73-9. [DOI: 10.1016/j.cbpa.2019.02.009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 29] [Article Influence: 5.7] [Reference Citation Analysis]
12 Jadav T, Jain S, Kalia K, Sengupta P. Current Standing and Technical Guidance on Intracellular Drug Quantification: A New Site Specific Bioavailability Prediction Approach. Critical Reviews in Analytical Chemistry 2020;50:50-61. [DOI: 10.1080/10408347.2019.1570462] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Tang J, Huber AD, Pineda DL, Boschert KN, Wolf JJ, Kankanala J, Xie J, Sarafianos SG, Wang Z. 5-Aminothiophene-2,4-dicarboxamide analogues as hepatitis B virus capsid assembly effectors. Eur J Med Chem 2019;164:179-92. [PMID: 30594676 DOI: 10.1016/j.ejmech.2018.12.047] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
14 Luo A, Jiang X, Ren H. Lamivudine plus tenofovir combination therapy versus lamivudine monotherapy for HBV/HIV coinfection: a meta-analysis. Virol J 2018;15:139. [PMID: 30201035 DOI: 10.1186/s12985-018-1050-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
15 Geng CA, Chen JJ. The Progress of Anti-HBV Constituents from Medicinal Plants in China. Nat Prod Bioprospect 2018;8:227-44. [PMID: 29978386 DOI: 10.1007/s13659-018-0178-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Sun X, Li D, Wang Z, Yin P, Hu R, Li H, Liu Q, Gao Y, Ren B, Zheng J, Wei Y, Liu T. Role of Protein Charge Density on Hepatitis B Virus Capsid Formation. ACS Omega 2018;3:4384-91. [PMID: 31458664 DOI: 10.1021/acsomega.8b00021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
17 Tsai HJ, Chuang YW, Lee SW, Wu CY, Yeh HZ, Lee T. Using the chronic kidney disease guidelines to evaluate the renal safety of tenofovir disoproxil fumarate in hepatitis B patients. Aliment Pharmacol Ther 2018;47:1673-81. [DOI: 10.1111/apt.14682] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
18 Granger E, Solomianko K, Young C, Erb J. Exploration of chiral Lewis acid Mg 2+ catalysts in the synthesis of aryl organophosphate triesters from phosphorus oxychloride through a three-step, two-pot substitution sequence. Tetrahedron Letters 2018;59:1404-8. [DOI: 10.1016/j.tetlet.2018.02.066] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
19 Liu X, Huang C, Xue L, Xu Q, Xia W, Li X, Miao L. Simultaneous determination of bentysrepinine (Y101) and its metabolites M8 and M9 in human plasma by UPLC–MS/MS and its application to a pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis 2018;150:287-93. [DOI: 10.1016/j.jpba.2017.12.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
20 Xu X, Xiang K, Su M, Li Y, Ji W, Li Y, Zhuang H, Li T. HBV Drug Resistance Substitutions Existed before the Clinical Approval of Nucleos(t)ide Analogues: A Bioinformatic Analysis by GenBank Data Mining. Viruses 2017;9:E199. [PMID: 28749433 DOI: 10.3390/v9080199] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
21 Sari O, Boucle S, Cox BD, Ozturk T, Russell OO, Bassit L, Amblard F, Schinazi RF. Synthesis of sulfamoylbenzamide derivatives as HBV capsid assembly effector. Eur J Med Chem 2017;138:407-21. [PMID: 28688280 DOI: 10.1016/j.ejmech.2017.06.062] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
22 Chen Q, Chen H, Wang W, Liu J, Liu W, Ni P, Sang G, Wang G, Zhou F, Zhang J. Glycyrrhetic acid, but not glycyrrhizic acid, strengthened entecavir activity by promoting its subcellular distribution in the liver via efflux inhibition. Eur J Pharm Sci 2017;106:313-27. [PMID: 28627473 DOI: 10.1016/j.ejps.2017.06.015] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
23 Zheng J, Lin X, Wang X, Zheng L, Lan S, Jin S, Ou Z, Wu J. In Silico Analysis of Epitope-Based Vaccine Candidates against Hepatitis B Virus Polymerase Protein. Viruses 2017;9:E112. [PMID: 28509875 DOI: 10.3390/v9050112] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 8.8] [Reference Citation Analysis]
24 Li ZQ, Hu CL, Yu P, Gu XY, Zhang JJ, Li H, Zhang HY, Lv J, Liu YM, Zeng QL, Yan JY, Yu ZJ, Zhang Y. The development of hepatocarcinoma after long-term antivirus treatment of Chinese patients with chronic hepatitis B virus infection: Incidence, long-term outcomes and predictive factors. Clin Res Hepatol Gastroenterol. 2017;41:311-318. [PMID: 28237828 DOI: 10.1016/j.clinre.2016.11.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
25 Pham EA, Perumpail RB, Fram BJ, Glenn JS, Ahmed A, Gish RG. Future Therapy for Hepatitis B Virus: Role of Immunomodulators. Curr Hepatol Rep 2016;15:237-44. [PMID: 27917363 DOI: 10.1007/s11901-016-0315-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
26 Li B, Sun S, Li M, Cheng X, Li H, Kang F, Kang J, Dörnbrack K, Nassal M, Sun D. Suppression of hepatitis B virus antigen production and replication by wild-type HBV dependently replicating HBV shRNA vectors in vitro and in vivo. Antiviral Res 2016;134:117-29. [PMID: 27591142 DOI: 10.1016/j.antiviral.2016.08.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
27 Boucle S, Bassit L, Ehteshami M, Schinazi RF. Toward Elimination of Hepatitis B Virus Using Novel Drugs, Approaches, and Combined Modalities. Clin Liver Dis 2016;20:737-49. [PMID: 27742011 DOI: 10.1016/j.cld.2016.07.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
28 Xie Y, Guo QS, Wang GS. Flavonoid Glycosides and Their Derivatives from the Herbs of Scorzonera austriaca Wild. Molecules 2016;21:E803. [PMID: 27338324 DOI: 10.3390/molecules21060803] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
29 Leng XJ, Yan XB. Status and development of anti-HBV drugs based on "HBF drug watch". Shijie Huaren Xiaohua Zazhi 2016; 24(15): 2336-2346 [DOI: 10.11569/wcjd.v24.i15.2336] [Reference Citation Analysis]
30 Afyon M. Letter: nucleos(t)ide analogues are good, but not sufficient for hepatitis B virus clearance. Aliment Pharmacol Ther 2016;43:654-5. [DOI: 10.1111/apt.13502] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]